Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.47
CRME's Cash to Debt is ranked higher than
58% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. CRME: 1.47 )
CRME' s 10-Year Cash to Debt Range
Min: 1.07   Max: No Debt
Current: 1.47

Equity to Asset 0.44
CRME's Equity to Asset is ranked higher than
59% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CRME: 0.44 )
CRME' s 10-Year Equity to Asset Range
Min: -0.01   Max: 0.99
Current: 0.44

-0.01
0.99
F-Score: 1
Z-Score: -5.67
M-Score: 29.01
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -65.46
CRME's Operating margin (%) is ranked higher than
74% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. CRME: -65.46 )
CRME' s 10-Year Operating margin (%) Range
Min: -12543.75   Max: 55.51
Current: -65.46

-12543.75
55.51
Net-margin (%) -70.38
CRME's Net-margin (%) is ranked higher than
73% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. CRME: -70.38 )
CRME' s 10-Year Net-margin (%) Range
Min: -12075   Max: 105.81
Current: -70.38

-12075
105.81
ROE (%) -75.57
CRME's ROE (%) is ranked higher than
62% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. CRME: -75.57 )
CRME' s 10-Year ROE (%) Range
Min: -126.66   Max: 93.63
Current: -75.57

-126.66
93.63
ROA (%) -42.88
CRME's ROA (%) is ranked higher than
66% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. CRME: -42.88 )
CRME' s 10-Year ROA (%) Range
Min: -101.1   Max: 46.31
Current: -42.88

-101.1
46.31
ROC (Joel Greenblatt) (%) -448.44
CRME's ROC (Joel Greenblatt) (%) is ranked higher than
73% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. CRME: -448.44 )
CRME' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4198.24   Max: 1509.37
Current: -448.44

-4198.24
1509.37
Revenue Growth (%) -58.60
CRME's Revenue Growth (%) is ranked higher than
58% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. CRME: -58.60 )
CRME' s 10-Year Revenue Growth (%) Range
Min: -75.7   Max: 288.2
Current: -58.6

-75.7
288.2
EBITDA Growth (%) -46.80
CRME's EBITDA Growth (%) is ranked higher than
55% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. CRME: -46.80 )
CRME' s 10-Year EBITDA Growth (%) Range
Min: -46.8   Max: 26.6
Current: -46.8

-46.8
26.6
EPS Growth (%) -48.00
CRME's EPS Growth (%) is ranked higher than
55% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. CRME: -48.00 )
CRME' s 10-Year EPS Growth (%) Range
Min: -48   Max: 24.4
Current: -48

-48
24.4
» CRME's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CRME Guru Trades in Q4 2013

Jim Simons 218,913 sh (+4.19%)
» More
Q1 2014

CRME Guru Trades in Q1 2014

Jim Simons 220,613 sh (+0.78%)
» More
Q2 2014

CRME Guru Trades in Q2 2014

Jim Simons 143,298 sh (-35.05%)
» More
Q3 2014

CRME Guru Trades in Q3 2014

Jim Simons 84,113 sh (-41.3%)
» More
» Details

Insider Trades

Latest Guru Trades with CRME

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Julian Robertson 2012-12-31 Sold Out 0.11%$0.25 - $0.5 $ 8.112516%0
George Soros 2011-12-31 Sold Out 0.0008%$1.87 - $3.57 $ 8.11203%0
Julian Robertson 2011-09-30 Reduce -22.89%0.69%$3.32 - $5.59 $ 8.11103%1952588
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.70
CRME's P/B is ranked higher than
73% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. CRME: 5.70 )
CRME' s 10-Year P/B Range
Min: 1.01   Max: 29.65
Current: 5.7

1.01
29.65
P/S 4.71
CRME's P/S is ranked higher than
89% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. CRME: 4.71 )
CRME' s 10-Year P/S Range
Min: 3.28   Max: 292.05
Current: 4.71

3.28
292.05
EV-to-EBIT -7.40
CRME's EV-to-EBIT is ranked higher than
79% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CRME: -7.40 )
CRME' s 10-Year EV-to-EBIT Range
Min: -18.7   Max: 96.3
Current: -7.4

-18.7
96.3
Current Ratio 2.60
CRME's Current Ratio is ranked higher than
63% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. CRME: 2.60 )
CRME' s 10-Year Current Ratio Range
Min: 1.14   Max: 97.75
Current: 2.6

1.14
97.75
Quick Ratio 2.18
CRME's Quick Ratio is ranked higher than
63% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. CRME: 2.18 )
CRME' s 10-Year Quick Ratio Range
Min: 1.14   Max: 97.75
Current: 2.18

1.14
97.75

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 20.61
CRME's Price/Tangible Book is ranked higher than
65% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. CRME: 20.61 )
CRME' s 10-Year Price/Tangible Book Range
Min: 1.1   Max: 69.88
Current: 20.61

1.1
69.88
Price/Median PS Value 0.18
CRME's Price/Median PS Value is ranked higher than
99% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. CRME: 0.18 )
CRME' s 10-Year Price/Median PS Value Range
Min: 0.16   Max: 92.31
Current: 0.18

0.16
92.31
Earnings Yield (Greenblatt) -13.50
CRME's Earnings Yield (Greenblatt) is ranked higher than
64% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. CRME: -13.50 )
CRME' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1   Max: 22.1
Current: -13.5

1
22.1
Forward Rate of Return (Yacktman) -3.68
CRME's Forward Rate of Return (Yacktman) is ranked higher than
79% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -6.41 vs. CRME: -3.68 )
CRME' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -178.8   Max: 16.1
Current: -3.68

-178.8
16.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
Traded in other countries:COM.Canada, CKO1.Germany
Cardiome Pharma Corp was incorporated on December 12, 1986. The Company is a specialty pharmaceutical company engaged in the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. It currently has two marketed, in-hospital, cardiology products, BRINAVESS, for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adultsand and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in Acute Coronary Syndrome patients. Both of its products are commercially available in numerous markets outside of the United States. BRINAVESS was approved in September 2010 and has been launched in the European Union, Iceland and Norway.
» More Articles for CRME

Headlines

Articles On GuruFocus.com
Julian Robertson’s "smart idea, grounded on exhaustive research, followed by a big bet" Jun 24 2011 
Julian Robertson’s Tiger Management Q1 Portfolio Update May 16 2011 
Julian Robertson Keeps Buying CRME, Selling AAPL Apr 13 2011 
More Word of Wisdom from Julian Robertson; Top 2Q10 Purchases: GOOG, EBAY, AAPL, CRME, GS Nov 04 2010 

More From Other Websites
Cardiome Enters Commercialization Agreement With Aspen For Brinavess In South Africa Nov 17 2014
Cardiome Enters Commercialization Agreement with Aspen for BRINAVESS® in South Africa Nov 17 2014
Cardiome Enters Commercialization Agreement with Aspen for BRINAVESS® in South Africa Nov 17 2014
Canada Stocks to Watch: TMX, InnVest, Brookfield, GMP and more Nov 07 2014
Cardiome Announces Positive Results From The BRINAVESS® Asia-Pacific Phase 3 Clinical Trial Nov 07 2014
Cardiome Submits BRINAVESS® Reimbursement Dossier To Italian Authorities To Support Market Access Nov 07 2014
Cardiome Reports Third Quarter 2014 Financial Results Nov 07 2014
Cardiome Announces Positive Results from the BRINAVESS® Asia-Pacific Phase 3 Clinical Trial Nov 07 2014
Cardiome Reports Third Quarter 2014 Financial Results Nov 07 2014
Cardiome Announces Positive Results from the BRINAVESS® Asia-Pacific Phase 3 Clinical Trial Nov 07 2014
Cardiome Submits BRINAVESS® Reimbursement Dossier to Italian Authorities to Support Market Access Nov 07 2014
Cardiome Submits BRINAVESS® Reimbursement Dossier to Italian Authorities to Support Market Access Nov 07 2014
Cardiome Reports Third Quarter 2014 Financial Results Nov 07 2014
Cardiome To Hold Third Quarter 2014 Financial Results Conference Call On November 7 Oct 31 2014
Cardiome to Hold Third Quarter 2014 Financial Results Conference Call on November 7 Oct 31 2014
Cardiome to Hold Third Quarter 2014 Financial Results Conference Call on November 7 Oct 31 2014
CARDIOME PHARMA (CRME) Enters Overbought Territory Sep 17 2014
Falling Earnings Estimates Signal Weakness Ahead for Cardiome Sep 10 2014
Cardiome Pharma Signs Agreement with Eurolab for Brinavess Aug 26 2014
Cardiome Enters Commercialization Agreement With Eurolab Especialidades Medicinales For BRINAVESS™... Aug 25 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK